Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Summary

The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses for 14 consecutive days.

Timeline

Start

2021-10

Primary completion

2022-11

Completion

2022-12

Drugs

Indications